VIATRIS INC. Cost of Revenue
VIATRIS INC. (VTRS) reported Cost of Revenue of $2.30 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- VIATRIS INC. cost of goods and services sold for the quarter ending 2026-06-30 was $2.30B, a 2.27% increase year-over-year.
- VIATRIS INC. cost of goods and services sold for the quarter ending 2026-03-31 was $2.36B, a 12.74% increase year-over-year.
- VIATRIS INC. cost of goods and services sold for the quarter ending 2025-12-31 was $2.56B, a 10.49% increase year-over-year.
- VIATRIS INC. cost of goods and services sold for the quarter ending 2025-09-30 was $2.39B, a 4.21% increase year-over-year.
- VIATRIS INC. cost of goods and services sold for fiscal 2025 was $9.29B, a 1.87% increase from fiscal 2024.
- VIATRIS INC. cost of goods and services sold for fiscal 2024 was $9.12B, a 1.42% increase from fiscal 2023.
- VIATRIS INC. cost of goods and services sold for fiscal 2023 was $8.99B, a 7.96% decline from fiscal 2022.
- VIATRIS INC. cost of goods and services sold for fiscal 2022 was $9.77B, a 20.67% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.30B 10-Q · filed 2026-08-06 | $4.66B 10-Q · filed 2026-08-06 | $7.22B derived: sum of 3 quarters · filed 2026-08-06 | $9.60B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.36B 10-Q · filed 2026-05-07 | $4.92B derived: sum of 2 quarters · filed 2026-05-07 | $7.30B derived: sum of 3 quarters · filed 2026-05-07 | $9.55B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.56B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.94B derived: sum of 2 quarters · filed 2026-02-26 | $7.19B derived: sum of 3 quarters · filed 2026-08-06 | $9.29B 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.39B 10-Q · filed 2025-11-06 | $4.64B derived: sum of 2 quarters · filed 2026-08-06 | $6.73B 10-Q · filed 2025-11-06 | $9.04B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.25B 10-Q · filed 2026-08-06 | $4.34B 10-Q · filed 2026-08-06 | $6.66B derived: sum of 3 quarters · filed 2026-08-06 | $8.95B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.09B 10-Q · filed 2026-05-07 | $4.41B derived: sum of 2 quarters · filed 2026-05-07 | $6.70B derived: sum of 3 quarters · filed 2026-05-07 | $9.05B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.31B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.61B derived: sum of 2 quarters · filed 2026-02-26 | $6.96B derived: sum of 3 quarters · filed 2026-02-26 | $9.12B 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.29B 10-Q · filed 2025-11-06 | $4.64B derived: sum of 2 quarters · filed 2025-11-06 | $6.80B 10-Q · filed 2025-11-06 | $9.04B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.35B 10-Q · filed 2025-08-07 | $4.51B 10-Q · filed 2025-08-07 | $6.75B derived: sum of 3 quarters · filed 2026-02-26 | $9.00B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.16B 10-Q · filed 2025-05-08 | $4.40B derived: sum of 2 quarters · filed 2026-02-26 | $6.65B derived: sum of 3 quarters · filed 2026-02-26 | $8.96B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.24B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.49B derived: sum of 2 quarters · filed 2026-02-26 | $6.80B derived: sum of 3 quarters · filed 2026-02-26 | $8.99B 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.25B 10-Q · filed 2024-11-07 | $4.56B derived: sum of 2 quarters · filed 2024-11-07 | $6.75B 10-Q · filed 2024-11-07 | $9.35B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.31B 10-Q · filed 2024-08-08 | $4.50B 10-Q · filed 2024-08-08 | $7.10B derived: sum of 3 quarters · filed 2025-02-27 | $9.43B derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.19B 10-Q · filed 2024-05-09 | $4.79B derived: sum of 2 quarters · filed 2025-02-27 | $7.12B derived: sum of 3 quarters · filed 2025-02-27 | $9.53B derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.60B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.93B derived: sum of 2 quarters · filed 2025-02-27 | $7.35B derived: sum of 3 quarters · filed 2025-02-27 | $9.77B 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.33B 10-Q · filed 2023-11-08 | $4.74B derived: sum of 2 quarters · filed 2023-11-08 | $7.16B 10-Q · filed 2023-11-08 | $9.96B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.41B 10-Q · filed 2023-08-07 | $4.83B 10-Q · filed 2023-08-07 | $7.63B derived: sum of 3 quarters · filed 2024-02-28 | $10.59B derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.42B 10-Q · filed 2023-05-08 | $5.22B derived: sum of 2 quarters · filed 2024-02-28 | $8.18B derived: sum of 3 quarters · filed 2024-02-28 | $11.43B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $2.80B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $5.76B derived: sum of 2 quarters · filed 2024-02-28 | $9.01B derived: sum of 3 quarters · filed 2024-02-28 | $12.31B 10-K · filed 2024-02-28 |
| 2021-09-30 | $2.96B 10-Q · filed 2022-11-07 | $6.21B derived: sum of 2 quarters · filed 2022-11-07 | $9.52B 10-Q · filed 2022-11-07 | $12.43B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $3.25B 10-Q · filed 2022-08-08 | $6.55B 10-Q · filed 2022-08-08 | $9.47B derived: sum of 3 quarters · filed 2023-02-27 | $11.28B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $3.30B 10-Q · filed 2022-05-09 | $6.22B derived: sum of 2 quarters · filed 2023-02-27 | $8.03B derived: sum of 3 quarters · filed 2023-02-27 | $9.74B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $2.92B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $4.73B derived: sum of 2 quarters · filed 2023-02-27 | $6.44B derived: sum of 3 quarters · filed 2023-02-27 | $8.15B 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.81B 10-Q · filed 2021-11-08 | $3.52B derived: sum of 2 quarters · filed 2021-11-08 | $5.23B 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $1.71B 10-Q · filed 2021-08-09 | $3.42B 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $1.71B 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $7.60B 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $7.43B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |